This is a Randomized, Open-Label, Phase 3 trial of brentuximab vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.
Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.
Millennium Pharmaceuticals, Inc.
Seattle Genetics, Inc.
St. James University Hospital
Leeds, United Kingdom, LS9 7TF
St. John's Institute of Dermatology
London, United Kingdom, SE1 EH
Manchester Cancer Research Centre
Manchester, United Kingdom, M20 4BX
For an updated listing of recruitment sites contact: Millennium Medical and Drug Information Center 1-877-674-3784 or email@example.com
This is an automatic translation service and therefore the
Cutaneous Lymphoma Foundation is not responsible
for any potential translation inaccuracies.